Opinion|Videos|September 18, 2024
Evaluating Imaging Agents in Oligometastatic Prostate Cancer: A Comparative Analysis of Gallium-Based and Non-Gallium-Based Options
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Medical experts conduct a comparative assessment of gallium-based and non-gallium-based imaging agents to determine their efficacy in detecting and characterizing oligometastatic prostate cancer.
Advertisement
Video content above is prompted by the following:
- Can you discuss the advantages and limitations of different imaging agents commonly used in identifying oligometastatic disease in prostate cancer, such as gallium-based agents versus non-gallium-based agents?
- Are you aware of any differences in lesion detection rates or staging accuracy between gallium vs non- gallium-based PET imaging agents?
Advertisement
Related to this article
In a recent interview, Carolynn DeBenedectis, MD, discussed the utility of AI-enabled slab reconstruction for interpretation of digital breast tomosynthesis (DBT) and new research showing a 13 percent reduction in reading time.
Keeping defensiveness and ego at bay is just one of the attributes of those who consistently embrace learning from others over the course of one’s life.
Catch up on the top radiology content of the past week.
In a recent interview, Gadi Lalazar, MD, discussed new research demonstrating the capability of natural language processing (NLP) to enhance recognition of incidental hepatic steatosis in ultrasound reports.
Report One, reportedly the first agentic reporting tool specifically geared to breast imaging, is one of three new products that will be showcased by MagView at the upcoming RSNA conference.
Artificial intelligence plaque analysis of CCTA scans showed that 27 percent of former NFL players had severe or extensive total plaque volume, according to a new study to be presented at the American Heart Association Scientific Sessions 2026 this week.
While the P4 trial represents a landmark study on the use of CCTA guidance for percutaneous coronary intervention (PCI), there are pertinent caveats that warrant closer inspection.
While contrast-enhanced mammography (CEM) offered the highest agreement with histopathology on the extent of malignancy in a new study, researchers found the use of pre-op CEM had no impact on mastectomy or reoperation rates.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
New Study Shows Benefits of AI Analysis for Ultrasound Reports and Incidental Findings of Hepatic Steatosis
2
Next-Generation Breast Imaging Platform to be Unveiled at RSNA
3
A Lyon Among Men: Handling Opportunities to Polish Your Radiology Game
4
Diagnostic Imaging’s Weekly Scan: November 1 — November 7
5